PARITY, INFLAMMATION, GESTATIONAL, AND TYPE 2 DIABETES MELLITUS

胎次、炎症、妊娠期和 2 型糖尿病

• 批准号: 7604656
• 负责人: Wanda K Nicholson
• 金额: $ 0.48万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604656
• 关键词: Blood Glucose; C-reactive protein; Clinical Research; Cohort Studies; Computer Retrieval of Information on Scientific Projects Database; Development; Diagnosis; Discipline of obstetrics; Fellowship; First Pregnancy Trimester; Funding; Gestational Diabetes; Glucose Intolerance; Grant; Gynecology; Inflammation; Inflammatory; Institution; Interleukin-6; Link; Longitudinal Studies; Measures; Mediating; Mentored Clinical Oncology Award; Mentored Clinical Scientist Award; Mentored Patient-Oriented Research Career Development Award; Non-Insulin-Dependent Diabetes Mellitus; Patients; Peer Review; Predictive Value; Pregnancy; Purpose; Recruitment Activity; Research; Research Personnel; Resources; Role; Second Pregnancy Trimester; Source; Third Pregnancy Trimester; Time; Training; Tumor Necrosis Factor-alpha; United States National Institutes of Health; Week; Woman; career; parity; professor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Wanda K. Nicholson, MD, MPH is seeking this K23 award to study the role of inflammatory markers as predictors of gestational diabetes mellitus (GDM) and incident Type 2 diabetes mellitus (Type 2 DM), to complete advanced training in the conduct of longitudinal studies, and to transition to an independent career in clinical research. Dr. Nicholson is an Assistant Professor in the Department of Gynecology and Obstetrics at Johns Hopkins and has fellowship training in clinical research and an early track record of peer reviewed clinical research. Parity has been previously linked to Type 2 DM; however, the underlying mechanism for this association is unclear. Recently, markers of inflammation (e.g. C-reactive protein) have emerged as independent predictors of Type 2 DM. No studies have examined whether the association of parity with Type 2 DM is mediated by the presence of inflammation. Moreover, it is unclear whether inflammatory markers are also predictors of GDM. The purpose of this study is to determine the effect of parity and inflammatory markers on development of gestational diabetes mellitus. We propose to conduct a case-cohort study in which we will recruit 300 women in the first trimester of pregnancy and measure inflammatory markers during the first, second, and third trimesters of pregnancy to determine the predictive value of inflammatory marker levels in the development of gestational diabetes mellitus. We plan to measure first, second, and third trimester levels of C-reactive protein, Interleukin-6, and tumor necrosis factor-alpha. In addition, we will obtain random glucose blood levels in the first and second trimester to identify any prevalent cases of glucose intolerance. We plan to conduct the study over a 16 month period in which we recruit patients and follow them up until the time of their diagnosis of gestational diabetes mellitus between 24 and 32 weeks of gestation.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 MPH的Wanda K. Nicholson医学博士正在寻求这一K23奖，以研究炎症标记作为妊娠糖尿病（GDM）（GDM）和事件2型糖尿病（2型DM）的预测因素（2型DM），以完成漫长研究的行为，以及过渡到独立职业的过渡。尼科尔森（Nicholson）博士是约翰·霍普金斯（Johns Hopkins）的妇科和妇产科系助理教授，并在临床研究中接受了奖学金培训，并且是同行评审的临床研究的早期记录。 以前已将奇偶校验链接到2型DM；但是，这种关联的基本机制尚不清楚。最近，炎症的标记（例如C反应蛋白）已成为2型DM的独立预测指标。尚无研究检查均衡与2型DM的关联是否是由炎症的存在介导的。此外，尚不清楚炎症标记是否也是GDM的预测指标。这项研究的目的是确定奇偶校验和炎症标志物对妊娠糖尿病发育的影响。 我们建议进行一项病例研究研究，其中我们将在怀孕的头三个月中招募300名妇女，并在妊娠的第一，第二和第三种三体中测量炎症标志物，以确定妊娠糖尿病发育中炎症标志物水平的预测价值。我们计划测量C反应蛋白，白介素-6和肿瘤坏死因子-Alpha的第一，第二和三个月水平。此外，我们将在第一和第二个三个月中获得随机的葡萄糖血液水平，以确定任何普遍的葡萄糖不耐症病例。我们计划在16个月的时间内进行研究，在该研究中，我们招募患者并跟进他们，直到妊娠24至32周之间诊断为妊娠糖尿病的诊断为止。